Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Caitlin Siebenaller, PharmD, Madeline Waldron, PharmD, BCOP, Kelly Gaffney, PharmD, Brian P. Hobbs, PhD, Ran Zhao, Marc Earl, PharmD, Marina Feldman, PharmD, BCCCP, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, MD, Aaron T. Gerds, MD MS, Bhumika J. Patel, MD, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2019) 134 (Supplement_1): 3433.

https://doi.org/10.1182/blood-2019-128807

Published: 2019

Journal Articles

Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety

Madeline Waldron, PharmD, Caitlin Siebenaller, PharmD, Marc Earl, PharmD, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, Aaron T. Gerds, MDMS, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Barb Tripp, CNS, Brian P. Hobbs, PhD, Sudipto Mukherjee, MD PhD MPH, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 712.

https://doi.org/10.1182/blood-2018-99-110029

Published: 2018

Journal Articles

Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis

Madeline Waldron, PharmD, Caitlin Siebenaller, PharmD, Brian P. Hobbs, PhD, Marc Earl, PharmD, Mary Schleicher, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, Aaron T. Gerds, MD MS, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2018) 132 (Supplement 1): 4805.

https://doi.org/10.1182/blood-2018-99-115256

Published: 2018

Journal Articles

Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay

Madeline Waldron, PharmD, Caitlin Siebenaller, PharmD, Marc Earl, PharmD, Xuefei Jia, MS, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, Aaron T. Gerds, MD MS, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Barb Tripp, CNS, Brian P. Hobbs, PhD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2018) 132 (Supplement 1): 4806.

https://doi.org/10.1182/blood-2018-99-115257

Published: 2018

Journal Articles

Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia

Di Sun, Paul Elson, Michaela Liedtke, MD, Bruno C. Medeiros, MD, Marc Earl, PharmD, RPh, Ash A Alizadeh, MD/PhD, Jennifer Bates, BS, CCRP, Mikkael A. Sekeres, MD, MS, Steven E. Coutre, MD, Matt Kalaycio, MD, Ronald Sobecks, MD, Edward Copelan, MD, Anjali S. Advani, MD

Blood (2011) 118 (21): 2552.

https://doi.org/10.1182/blood.V118.21.2552.2552

Published: 2011

Journal Articles

Fluoroquinolone Prophylaxis in Acute Myeloid Leukemia (AML) Patients Undergoing Post-Remission Chemotherapy Reduces Hospital Admission Rates

Karissa Kusick, PharmD, RPh, Marc Earl, PharmD, RPh, Erika M. Gallagher, PharmD, BCOP, Jun-Yen Yeh, PhD, Anjali S. Advani, MD, Matt Kalaycio, MD, Edward A. Copelan, MD, Mikkael A. Sekeres, MD, MS

Blood (2011) 118 (21): 2570.

https://doi.org/10.1182/blood.V118.21.2570.2570

Published: 2011

Journal Articles

Outcomes in Obese and Overweight Acute Myeloid Leukemia (AML) Patients Receiving Chemotherapy Dosed According to Actual Body Weight

Erika M. Gallagher, PharmD, BCOP, Marc Earl, PharmD, RPh, Jun-Yen Yeh, PhD, Karissa Kusick, PharmD, RPh, Jaclyn Kruse, PharmD Candidate, Caitlin Swann, PharmD Candidate, April Smith, Randall Davis, Anjali S. Advani, MD, Matt Kalaycio, MD, Edward A. Copelan, MD, Mikkael A. Sekeres, MD, MS

Blood (2011) 118 (21): 1496.

https://doi.org/10.1182/blood.V118.21.1496.1496

Published: 2011

Journal Articles

Prior Therapy with DNA Methyltransferase Inhibitors (DNMTI) Predicts for Lower Remission Rates and Worse Survival In Secondary Acute Myeloid Leukemia Patients (sAML) Receiving Remission Induction Therapy

Sanjay R. Mohan, MD, Alex Fu, Ramon V. Tiu, MD, Edward Copelan, MD, Yogen Saunthararajah, MD, Anjali Advani, MD, Ronald Sobecks, MD, Manual Afable, Ricki Englehaupt, Katarina Paulic, Marc Earl, Pharm., D., R.Ph., Matt Kalaycio, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 4033.

https://doi.org/10.1182/blood.V116.21.4033.4033

Published: 2010

Journal Articles

Intrathecal Chemotherapy Prophylaxis for CNS Relapse of DLBCL In the RCHOP Era: A Single Center Analysis.

Christopher Scott Kovacs, Jr., MD, John William Sweetenham, MD, FRCP, Marc Earl, Pharm., D., R.Ph., Robert Dean, MD, Brad Pohlman, MD, Brian Bolwell, MD, Stephen D. Smith, MD, BS

Blood (2010) 116 (21): 2804.

https://doi.org/10.1182/blood.V116.21.2804.2804

Published: 2010

Journal Articles

Outcomes In Acute Myeloid Leukemia (AML) Patients Diagnosed with Myeloid Sarcoma with and without Bone Marrow Involvement

Marc Earl, Pharm., D., R.Ph., Alex Fu, Matt Kalaycio, MD, Anjali Advani, MD, Yogen Saunthararajah, MD, Christina Piks, Barb Tripp, Kristy Grimes, Ronald Sobecks, MD, Edward Copelan, MD, Jaroslaw Maciejewski, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 2165.

https://doi.org/10.1182/blood.V116.21.2165.2165

Published: 2010

Journal Articles

The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML).

Mikkael A. Sekeres, MD, MS, Alex Z Fu, PhD, Marc Earl, PharmD, Matt Kalaycio, MD, Anjali Advani, MD, Yogen Saunthararajah, M.D., Ronald Sobecks, MD, Edward Copelan, MD

Blood (2009) 114 (22): 1043.

https://doi.org/10.1182/blood.V114.22.1043.1043

Published: 2009

Journal Articles

Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML).

Anna K Brady, BS, BA, Alex Z Fu, PhD, Marc Earl, PharmD, Matt Kalaycio, Anjali Advani, MD, Yogen Saunthararajah, M.D., Ronald Sobecks, Edward Copelan, MD, Mikkael A. Sekeres, MD, MS

Blood (2009) 114 (22): 1012.

https://doi.org/10.1182/blood.V114.22.1012.1012

Published: 2009

Journal Articles

Toxicities in Adults with Acute Lymphoblastic Leukemia (ALL) Treated with Regimens Using Pegasparaginase.

Michael Rytting, M.D., Marc Earl, PharmD, Dan Douer, MD, Brenda Muriera, RN, Anjali Advani, MD, Archie Bleyer, MD

Blood (2008) 112 (11): 1924.

https://doi.org/10.1182/blood.V112.11.1924.1924

Published: 2008

Journal Articles

Toxicities of Intravenous (IV) Pegasparaginase (ONCASPAR®) in Adults with Acute Lymphoblastic Leukemia (ALL).

Anjali Advani, MD, Marc Earl, PharmD, Dan Douer, MD, Michael Rytting, MD, Archie Bleyer, MD

Blood (2007) 110 (11): 2811.

https://doi.org/10.1182/blood.V110.11.2811.2811

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety

Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis

Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay

Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia

Fluoroquinolone Prophylaxis in Acute Myeloid Leukemia (AML) Patients Undergoing Post-Remission Chemotherapy Reduces Hospital Admission Rates

Outcomes in Obese and Overweight Acute Myeloid Leukemia (AML) Patients Receiving Chemotherapy Dosed According to Actual Body Weight

Prior Therapy with DNA Methyltransferase Inhibitors (DNMTI) Predicts for Lower Remission Rates and Worse Survival In Secondary Acute Myeloid Leukemia Patients (sAML) Receiving Remission Induction Therapy

Intrathecal Chemotherapy Prophylaxis for CNS Relapse of DLBCL In the RCHOP Era: A Single Center Analysis.

Outcomes In Acute Myeloid Leukemia (AML) Patients Diagnosed with Myeloid Sarcoma with and without Bone Marrow Involvement

The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML).

Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML).

Toxicities in Adults with Acute Lymphoblastic Leukemia (ALL) Treated with Regimens Using Pegasparaginase.

Toxicities of Intravenous (IV) Pegasparaginase (ONCASPAR®) in Adults with Acute Lymphoblastic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only